Circio announces that the ongoing feasibility study with a major global pharmaceutical corporation is progressing to in vivo testing

Circio Holding ASA

Oslo, Norway, 24 April 2026 -- Circio Holding ASA (OSE: CRNA), a biotechnology
company developing novel circular RNA expression technology for gene and cell
therapy, today announces that the previously reported feasibility study with
one of the major global pharmaceutical corporations is progressing to the next
phase of testing.

Reference is made to the stock exchange notice by Circio on 18 November 2025
(https://www.circio.com/en/circio-enters-fully-funded-feasibility-study-with-maj
or-global-pharmaceutical-corporation/),
announcing a feasibility study with a major global pharmaceutical company. The
project involves testing of Circio's circVec circular RNA expression
technology for delivery with AAV vectors in a specific therapeutic area.
Initial technical testing in vitro has now been successfully completed, and
certain circVec candidates have been selected for further testing in vivo. The
project is performed by Circio and is fully funded by the pharmaceutical
company. The agreement does not include any downstream rights or obligations
on either party.

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA
expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 50-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation (MAR) and is subject to the disclosure requirements
pursuant to MAR and section 5-12 of the Norwegian Securities Trading Act. The
information was submitted for publication at 2026-04-24 22:00 CEST.

This stock exchange announcement was published by Mats Hermansen, VP Finance,
on behalf of the Company, at the time and date stated above in this
announcement.

More information:
Access the news on Oslo Bors NewsWeb site